Septerna, Inc. Common Stock (SEPN) Stock Price

SEPNStock

$36.35+61.09%52W

Market Cap$1.70B

P/E—

PEG Ratio—

Div yield—

Beta0.94

SEPN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)40.74%

Price vs S&P 500 (4W)-4.36%

VGM Score72.55

P/CF (Annual)15.40x

Book Value / Share (Quarterly)$8.47

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$2.30

Price vs S&P 500 (YTD)18.45%

Net Profit Margin (TTM)-24.51%

EPS (TTM)$-0.54

10-Day Avg Trading Volume0.45M

EPS Excl Extra (TTM)$-0.54

EPS (Annual)$-1.10

ROI (Annual)-12.80%

Cash / Share (Quarterly)$8.15

Revenue Growth QoQ (YoY)22375.63%

ROA (Last FY)-8.20%

Revenue Growth TTM (YoY)13520.11%

EBITD / Share (TTM)$-0.93

Operating Margin (TTM)-44.04%

Cash Flow / Share (Annual)$2.45

P/B Ratio4.39x

P/B Ratio (Quarterly)3.90x

Net Income / Employee (Annual)$-376,000

EV / Revenue (TTM)16.30x

ROA (TTM)-4.14%

EPS Incl Extra (Annual)$-1.10

Current Ratio (Annual)4.73x

Quick Ratio (Quarterly)4.90x

3-Month Avg Trading Volume0.43M

52-Week Price Return61.09%

EV / Free Cash Flow (Annual)14.70x

Revenue / Employee (TTM)$760,600

P/S Ratio (Annual)36.92x

Asset Turnover (Annual)0.08x

52-Week High$51.10

EPS Excl Extra (Annual)$-1.10

26-Week Price Return50.64%

Quick Ratio (Annual)4.67x

13-Week Price Return8.83%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.99x

Enterprise Value$1.61B

Asset Turnover (TTM)0.17x

Revenue / Employee (Annual)$353,500

Pretax Margin (Annual)-106.35%

Cash / Share (Annual)$8.73

3-Month Return Std Dev66.10%

Net Income / Employee (TTM)$-186,400

ROE (Last FY)-12.80%

EPS Basic Excl Extra (Annual)$-1.10

Receivables Turnover (TTM)16.06x

EV / Free Cash Flow (TTM)15.34x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.54

Receivables Turnover (Annual)8.73x

ROI (TTM)-6.31%

P/S Ratio (TTM)17.16x

Revenue / Share (Annual)$1.04

Price vs S&P 500 (52W)45.56%

Year-to-Date Return30.38%

5-Day Price Return-3.22%

EPS Normalized (Annual)$-1.10

Net Profit Margin (Annual)-106.37%

Month-to-Date Return-7.10%

EBITD / Share (Annual)$-1.51

Operating Margin (Annual)-148.63%

P/CF (TTM)16.01x

EPS Basic Excl Extra (TTM)$-0.54

P/B Ratio (Annual)3.27x

Pretax Margin (TTM)-23.17%

Book Value / Share (Annual)$8.52

Price vs S&P 500 (13W)6.15%

Beta0.94x

P/FCF (Annual)15.47x

Revenue / Share (TTM)$2.20

ROE (TTM)-6.31%

52-Week Low$17.55

vGradeD

gGradeA

mGradeA

vgmGradeB

SEPN Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 10, 2026	-$0.49	-$0.29	+41.19%(+$0.20)
Q1 2026	May 11, 2026	-$0.27	-$0.19	+30.76%(+$0.08)
Q4 2025	Mar 9, 2026	-$0.22	-$0.24	-8.54%(-$0.02)
Q3 2025	Nov 10, 2025	$0.79	-$0.10	-112.30%(-$0.89)
Q2 2025	Aug 11, 2025	$0.93	-$0.56	-160.41%(-$1.49)

SEPN Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.20

4.25

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
SEPNSepterna, Inc. Common Stock	D	A	A	17.2x	13520.1%	—	—	$36.35
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Septerna, Inc. Common Stock

Septerna Inc is a clinical-stage biotechnology company developing oral small molecule therapies targeting G protein-coupled receptors (GPCRs) using its proprietary Native Complex Platform. The company's pipeline addresses endocrinology, immunology/inflammation, and metabolic diseases, with lead candidates including SEP-786 (PTH1R), SEP-631 (MRGPRX2), and programs in GLP-1R, GIPR, GCGR, and TSHR. By enabling drug discovery against historically challenging GPCR targets, Septerna aims to address conditions with significant unmet medical needs.

SEPN Next Earnings Report

Report dateNov 9, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate-$0.40

Revenue estimate$20.78M

Also reporting on Nov 9, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

SEPN Insider Transactions

SellSep 1, 2026
LONG DANIEL D
Officer
Shares: 3,333Value: $126,078
SellAug 12, 2026
RA CAPITAL MANAGEMENT, L.P.
Beneficial Owner of more than 10% of a Class of Security
Shares: 1,493,000Value: $63.45M
SellAug 12, 2026
THIRD ROCK VENTURES V, L.P.
Beneficial Owner of more than 10% of a Class of Security
Shares: 147,200Value: $7.40M
SellAug 11, 2026
BHATT ELIZABETH
President
Shares: 25,000Value: $1.10M
SellAug 3, 2026
LONG DANIEL D
Officer
Shares: 3,334Value: $114,920

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

NVAXNovavax IncBiological Products
ALVOAlvotech Ordinary SharesBiological Products
OLNOlin Corp.Chemicals
MESOMesoblast Limited American Depositary SharesBiological Products
VIRVir Biotechnology, Inc. Common StockBiological Products
NTLAIntellia Therapeutics, IncIn Vitro Diagnostics
MAZEMaze Therapeutics, Inc. Common StockBiological Products
IMCRImmunocore Holdings plc American Depositary SharesBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.3

Strong Buy

Consensus rating

52-Week Range

Low$17.55

High$51.10